The Hashish plant has been used for a lot of of years as a medicinal agent within the aid of ache and seizures. It accommodates roughly 540 pure compounds together with greater than 100 which were recognized as phytocannabinoids attributable to their shared chemical construction. The predominant psychotropic element is Δ9-tetrahydrocannabinol (Δ9-THC), whereas the main non-psychoactive ingredient is cannabidiol (CBD). These compounds have been proven to be partial agonists or antagonists on the prototypical cannabinoid receptors, CB1 and CB2. The therapeutic actions of Δ9-THC and CBD embody a capability to behave as analgesics, anti-emetics, anti-inflammatory brokers, anti-seizure compounds and as protecting brokers in neurodegeneration. Nonetheless, there’s a lack of well-controlled, double blind, randomized medical trials to supply readability on the efficacy of both Δ9-THC or CBD as therapeutics. Furthermore, the protection considerations relating to the undesirable negative effects of Δ9-THC as a psychoactive agent preclude its widespread use within the clinic. The legalization of cannabis for medicinal functions and for leisure use in some areas will permit for a lot wanted analysis on the pharmacokinetics and pharmocology of medical cannabis. This transient evaluation focuses on the usage of cannabis as a medicinal agent within the therapy of ache, epilepsy and neurodegenerative illnesses. Regardless of the paucity of data, consideration is paid to the mechanisms by which medical cannabis could act to alleviate ache and seizures.